Status:
UNKNOWN
Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
Lead Sponsor:
Hui Bu
Conditions:
Leptomeningeal Metastasis
Durvalumab
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to observe the clinical efficacy and safety of Durvalumab combined with intrathecal chemotherapy in non-small cell lung cancer with leptomeningeal metastasis
Eligibility Criteria
Inclusion
- Male and Female age 18 or more
- Pathologically proven non-small cell lung cancer
- MRI(Magnetic Resonance Imaging,MRI) imaging findings or the detection of malignant cells in cerebrospinal fluid
- Patients have the ability to understand and the willingness to sign a written informed consent document.
Exclusion
- KPS score \<60
- History of autoimmune diseases
- With severe hepatic and renal dysfunction
- Has a history of (non-infectious) pneumonitis that required steroids
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04356222
Start Date
June 1 2020
End Date
June 1 2023
Last Update
May 27 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.